GALAFOLD (migalastat), previously available through the Life Saving Drug Program, is now listed on the PBS with expanded eligibility for patients aged 12 and older with specific genetic mutations affecting their organs.
Fabry disease, a rare genetic condition, leads to fat build-up causing pain, hearing loss, and potentially life-threatening complications like kidney and heart disease.
The PBS listing is expected to benefit around 65 patients annually, saving families up to $330,000 per year.
Additionally, the PBS will also expand coverage of Cabometyx (cabozantinib) to treat non-clear cell renal cell carcinoma.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Sep 24
